SCHEMBL1878730

SCHEMBL1878730

COC(=O)c1ccn(Cc2ccccc2)c1C(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.51
KDM4E B2RXH2 2/20 0.44
BRD4 O60885 3/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
BRDT Q58F21 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
HSP90B1 P14625 1/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
AR P10275 1/20 0.41
CYP1A2 P05177 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1879152 0.85 NOTUM (0.65) NOTUMKDM4EBRD4BRD2BRD3
SCHEMBL4273292 0.79 NOTUM (0.52) NOTUMKDM4EBRD4BRD2BRD3
SCHEMBL14452607 0.78 BRD4 (0.56) NOTUMKDM4EBRD4BRD2BRD3
SCHEMBL1877442 0.77 MAPT (0.49) NOTUMKDM4EMEN1KMT2AMAPT
SCHEMBL1882299 0.76 TSHR (0.55) NOTUMKDM4EKMT2AMAPTTHRB
SCHEMBL1137191 0.74 BRD4 (0.70) KDM4EBRD4BRD2BRD3BRDT
SCHEMBL10019032 0.74 PTGER4 (0.49) NOTUMKDM4EBRD4BRD2BRD3
SCHEMBL701030 0.74 NR4A2 (0.53) MEN1KMT2AL3MBTL1CYP1A2HTT
SCHEMBL1884213 0.74 MAPT (0.46) NOTUMKDM4EMEN1KMT2AMAPT
SCHEMBL1880402 0.74 MAPT (0.46) NOTUMKDM4EBRD4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity ALLERGAN, INC. (US) 2011-05-05 US disclosed
EP-2185506-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2010-05-19 EP disclosed
WO-2009026407-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity S1PR1, S1PR2, S1PR3 NOTUM 822/4885KDM4E 3350/4885BRD4 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.